Clinical Trials
Genzyme Announces Results of Phase 3 Trial of Clolar in Adult AML
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML). Although the study did not...
Clinical Trials
Boehringer Ingelheim announced approval for TWYNSTA®. TWYNSTA single pill combination that delivers powerful and consistent blood pressure reductions
Boehringer Ingelheim announced today that the European Commission confirmed the positive opinion of the European Medicines Agency (EMA) approving TWYNSTA®. TWYNSTA® is indicated for the treatment of hypertension in adults whose blood pressure is not adequately controlled on amlodipine...
Clinical Trials
Amgen announced that results from the PRIME ‘203’ and ‘181’ pivotal Phase 3 trials
Amgen announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix(R) (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online...
Clinical Trials
Bristol-Myers Squibb announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes
Bristol-Myers Squibb Company and AstraZeneca announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes inadequately controlled on metformin therapy alone. The study demonstrated dapagliflozin was non-inferior compared to glipizide (sulphonylurea) in improving...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
